Colloidal bismuth subcitrate as coated tablets: four times versus twice daily dosage in duodenal ulcer

Scand J Gastroenterol Suppl. 1986:122:51-3. doi: 10.3109/00365528609102588.

Abstract

Forty patients with endoscopically proven duodenal ulceration have cooperated in a clinical trial to compare the ulcer healing effect of colloidal bismuth subcitrate (CBS) at standard dosage administered either twice or four times a day. No statistically significant difference was found to exist between ulcer healing in the two groups after 4 weeks (70% and 95%, respectively), and it is concluded that twice daily CBS is an effective treatment for duodenal ulcer with clear advantages as regards patient cooperation.

Publication types

  • Clinical Trial
  • Comparative Study
  • Controlled Clinical Trial

MeSH terms

  • Adult
  • Bismuth / administration & dosage*
  • Clinical Trials as Topic
  • Drug Administration Schedule
  • Duodenal Ulcer / drug therapy*
  • Female
  • Humans
  • Male
  • Middle Aged
  • Organometallic Compounds*
  • Tablets

Substances

  • Organometallic Compounds
  • Tablets
  • bismuth tripotassium dicitrate
  • Bismuth